Filing Date 2013-02-14
http://www.sec.gov/Archives/edgar/data/1317880/000126246313000072/plpl10q.htm
Security Details
Plandai Biotechnology, Inc. is a fully reporting SEC company, publicly traded on the OTC Market under the symbol, "PLPL". As such, Business, operational and financial information on PLPL is fully transparent and available to public view.
A/S : 500 million confirmed / State of Nevada O/S : 110,895,300 (as of January 31st, 2013 )
Dilution: 9,500,000 (since December 2011)
Free Float: 15,000,000 (May 2013)
Incorporated in: NV,USA
Year of Inc.: 2012
Transfer Agent
Signature Stock Transfer, Inc.
Transfer Agent, 2632 Coachlight Ct., Plano, TX, 75093
972-612-4120
SignatureStock@aol.com
___________________________________________________________________________________________________________________________________________________________________________________________________________________ 15 May 2013 Plandai Biotechnology, Inc. Announces Positive Anti-Malaria Test Results Using Phytofare™ Extract Plandai Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical and pharmaceutical, today announced that the Company's Phytofare™ Catechin Extract has proven effective in killing the malaria parasite, plasmodium falciparum, in analytical tests developed by and conducted under the supervision of Dr. Sanjeev Krishna at the Division of Cellular and Molecular Medicine, Centre for Infection, St George's, London School of Medicine.
In the study, the single and most dominant catechin - Epigallocatechin Gallate (EGCG) - was isolated from Plandai's Phytofare™ extract and its effectiveness compared in killing the P. falciparum parasite against a purified EGCG extract. The results, which are expected to be published soon, showed that the Phytofare™ extract killed the parasite and with a lower dosage than the purified EGCG extract.
Roger Duffield, Chief Executive Officer of Plandai, commented, "These initial findings provide evidence corroborating previous scientific findings that Epigallocatechin Gallate catechin can kill the malaria parasite. This study involving Phytofare™ is the first to show the effectiveness of using a commercial botanical extract, rather than purified extract of EGCG catechin, as an anti-malarial.
"We believe these results validate our decade-long research into the opportunity for using botanical extracts as a means to combat one of the world's great plagues. Dr. Krisha's clinical data indicate that Phytofare™ extract has a stable platform with predictable outcomes, making it a suitable candidate for further investigations. We now have the opportunity evaluate the extract in further studies, including inhibiting the parasite in the glucose transporter and as a potential prophylactic by destroying the sporozoites during their journey from injection into the human blood by the female mosquito to the liver."
Plandai is finalizing agreements to undertake further in vitro and then mouse studies at the University of Cape Town, Department of Clinical Pharmacology, to further validate the antimalarial drug target through greater synergistic activity of the complete Phytofare™ catechin complex containing the total eight catechins, rather than the single isolated Epigallocatechin Gallate (EGCG).
Once all these results have been evaluated, the Company will submit its application with the US Food and Drug Administration to commence Phase II human clinical trials.
Each year, approximately 500 million people worldwide become infected with malaria. Of those infected, roughly 600,000 will die from the disease. The development of vaccine options has so far proved challenging due to the complexity of the parasite. In addition, drug-resistant strains of the parasite are moving across Southeast Asia, prompting the need to develop a new line of drug options. 9 May 2013
Plandai Biotechnology, Inc. Announces Distribution Agreement With Natural Products For Weight Management Product Using Phytof...
Plandai Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced a distribution agreement which grants Natural Products the exclusive rights in South Africa to develop and market a weight management product using Plandai's Phytofare™ Catechin Extract. Natural Products specializes in producing and selling Maxi™ nutraceuticals through an Internet client base and directly to pharmacists and wellness retailers in South Africa.
Plandai's Phytofare™ Catechin Extract is processed to deliver a highly bioavailable, antioxidant-rich material to a level many times that of other green tea extracts available on the market. Research has shown that green tea gallate catechins are extremely active antioxidants and in a bioavailable form, are able to protect the red and white blood cells against attack. While not a cure, Phytofare™ Catechin Extract offers meaningful disease prevention, particularly for patients suffering from a compromised immune system, through infections, viruses, malaria and other parasitic infections.
Green tea has long been recognized for its weight management benefits including fat reduction, increased metabolism and improved endurance during exercise. These benefits will be the focus of the weight loss product using Phytofare™ Catechin Extract.
"Natural Products is a dynamic and innovative South African company, and we believe it will excel in developing and marketing a weight loss product using Phytofare™ Catechin Extract," said Callum Baylis-Duffield, Vice-President and Global Director, Marketing Sales for Plandai Biotechnology.
"We are excited to have the opportunity to work with Plandai on the development of this weight management product and believe it has tremendous potential in the South Africa market," said Warren Booth of Natural Products."
In published USDA studies, Plandai's proprietary plant extracts, including Phytofare™ Catechin Extract, Phytofare™ Glucoside Complex and Phytofare™ Carotenoid Extract, have shown to have improved bioavailability – the degree to which a substance becomes available to the target tissue after administration – of between 60-80%, far exceeding anything available today. Superior levels of bioavailability simply mean that the body can actually receive the benefits promised on the product label.
The Company believes that its technology is the foundation for creating an entirely new family of drugs that can treat a multitude of diseases and conditions safely and affordably using naturally-derived extracts. _____________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________
For additional press releases please visit: www.plandaibiotech.com/press-release.html
May 2013 | |
Marketwire
(Thurs, May 9) | Plandai Biotechnology, Inc. Announces Distribution Agreement With Natural Products For Weight Management Product Using Phytofare™ Catechin Extract |
Marketwire
(Wed, May 8) | Plandai Biotechnology, Inc. Molecularly Changing the Botanical Extract Industry |
Marketwire
(Tues, May 7) | Plandai Biotechnology, Inc. Announces Formation Of New Entity To Develop Pharmaceutical Applications |
Marketwire
(Thurs, May 2) | Plandai Biotechnology, Inc. Expands Global Distribution Of Phytofare™ Extracts With Agreement For European Markets |
Marketwire
(Wednesday, May 1) | Stock House Group Report Initiates Coverage on Plandai Biotechnology, Inc. |
April 2013 | |
Marketwire
(Mon, April 29) | Plandai Biotechnology, Inc. Announces Distribution Agreement With NutraGenesis For Phytofare™ Extracts |
Marketwire
(Wed, April 24) | Plandai Biotechnology, Inc. Announces Shipment Of First Machinery To South African Production Facility |
Marketwire
(Mon, April 22) | Plandai Biotechnology, Inc. Enters Into License Agreement With Phyto Nutricare To Develop Nutraceutical Products |
Marketwire
(Thurs, April 18) | Teva More Undervalued Than Mylan, Looks Towards Technology |
Marketwire
(Mon, April 8) | Plandai Biotechnology, Inc. Updates Progress Of Preparing Products For Market |
_____________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________
Management Team
Roger Duffield
President, Chief Executive officer and member of the Board of Directors
Callum Baylis-Duffield
Vice-President and Global Director: Marketing
Sales
David Rzepnicki
Chief Financial Officer and member of the Board of Directors
Tim Matula
Investor Relations and member of the Board of Directors
Contact:
Corporate Headquarters
Address: 2226 Eastlake Ave E, #156
Seattle, Washington, 98102, USA
Phone: (425) 466-0212
Website: http://www.plandaibiotech.com Email: Info@plandaibiotech.com 